Nonetheless, given the anti-neoplastic effect of targeting B7-H3 in GBM, several phase I trials using CAR-T therapy are currently underway (NCT05241392, NCT04385173, NCT04077866, NCT05366179). This evidence concerns the gene CD276 and glioblastoma.